Dr. Francesca Bedussi, M.D.
F. Bedussi - Clinical Pharmacology and Toxicology in the Context of Addiction
SUPSI Image Focus
Dr. Francesca Bedussi, M.D., a specialist in Pharmacology and Clinical Toxicology at the EOC, completed the CAS Addiction program. She particularly appreciated the interdisciplinary dialogue and collaboration among services, which enabled her to put what she had learned into practice by developing a protocol for the care of pregnant women with substance use disorders.
The reality surrounding the world of addiction forms a complex and ever-changing tapestry that is not always easy to understand, even for professionals in the field. It is a constantly evolving landscape, shaped by the times, influenced by networks of prevention, care, and intervention, and guided by the operational drive of community-based services and the creativity of organizations striving to address changes in phenomena linked not only to substance use but also to those where substances are not involved and where addiction stems from specific behaviors. Intervening in these areas today raises numerous questions and highlights the need for constant updating and discussion regarding the most effective approaches that can be implemented in the multifaceted contexts where addictive behaviors emerge. As the Federal Office of Public Health points out, the risks to individuals and society associated with these phenomena require ongoing education in this field.
SUPSI’s Continuing Education Program in Social Work, in collaboration with Ticino Addiction and with the support of the Federal Office of Public Health and the Public Health Division of the Department of Social Affairs (DSS) of the Canton of Ticino, will offer the CAS in Addiction from April 20, 2027, through June 6, 2028, a professional development opportunity based on the integration of socio-pedagogical and care perspectives, aimed at fostering exchanges and interactions to bring about innovative cultural and operational changes in the functioning of services and networking.
Below is an article by Dr. Francesca Bedussi, M.D., a specialist in pharmacology and clinical toxicology at the Institute of Pharmacological Sciences of Italian-speaking Switzerland at the Ente Ospedaliero Cantonale (EOC), who certified the CAS Addiction program in its previous edition by developing a protocol for patient care within her workplace through rigorous research and in-depth analysis.
SUPSI’s Continuing Education Program in Social Work, in collaboration with Ticino Addiction and with the support of the Federal Office of Public Health and the Public Health Division of the Department of Social Affairs (DSS) of the Canton of Ticino, will offer the CAS in Addiction from April 20, 2027, through June 6, 2028, a professional development opportunity based on the integration of socio-pedagogical and care perspectives, aimed at fostering exchanges and interactions to bring about innovative cultural and operational changes in the functioning of services and networking.
Below is an article by Dr. Francesca Bedussi, M.D., a specialist in pharmacology and clinical toxicology at the Institute of Pharmacological Sciences of Italian-speaking Switzerland at the Ente Ospedaliero Cantonale (EOC), who certified the CAS Addiction program in its previous edition by developing a protocol for patient care within her workplace through rigorous research and in-depth analysis.
The Department of Clinical Pharmacology and Toxicology is part of the Institute of Pharmacological Sciences of Italian-speaking Switzerland at the Cantonal Hospital Authority (EOC). The Institute’s physicians provide consultation services to inpatients and outpatients on all clinical aspects related to medications.
Based on my clinical experience, I developed—as part of my final project for the CAS Addiction program—a structured protocol for the pharmacological and toxicological management of pregnant patients diagnosed with substance use disorder (SUD), which was developed based on an analysis of existing services in the region.
The use of legal (e.g., alcohol, nicotine) and/or illegal substances by women with DUS during pregnancy is a growing public health concern. Substance use during pregnancy increases the risk of adverse outcomes for both mother and child, including higher rates of morbidity and mortality, as well as potential consequences for neurodevelopment in later years. As an institute, we are often called upon to assess exposure to medications and substances during pregnancy. The presence of a substance use disorder makes intervention particularly complex, as it occurs within the context of poly-substance use and comorbidities—often psychiatric in nature—that require appropriate pharmacological treatments even during pregnancy. This takes place against a backdrop that is highly fragile from a biopsychosocial and relational standpoint, necessitating support for future parenthood and attention to legal and ethical implications.
Structured interviews were conducted with representatives of the services identified as being most involved: the Ingrado Addiction Service, the Cantonal Prison Health Service, the Cantonal Psychiatric Clinic of the Cantonal Sociopsychiatric Organization (OSC), and the OSC Psychosocial Services. In addition, the EOC departments that serve as the primary points of contact with women of childbearing age who use substances but are not being treated by specialized services (Emergency Department, Gynecology and Obstetrics, Infectious Diseases, Sexual Health Clinics, Neonatology) were identified, recognizing the crucial role of primary care physicians and pediatricians in the community.
According to all healthcare providers, in most cases patients arrive already pregnant, often with psychiatric comorbidities and on medication—sometimes complex; it is uncommon for them to request preconception optimization of their treatment to plan for pregnancy. The most commonly involved substances are cocaine, heroin, and cannabis, with an increase in cases related to stimulants (amphetamines, synthetic cathinones) and ketamine; among legal substances, alcohol, nicotine, and benzodiazepines are common. The family situation upon discovery of the pregnancy is often complex, and it is not uncommon for there to be no stable partner.
In summary, there appears to be a lack of shared protocols for the care of pregnant women with substance use disorders (SUD), posing a risk of fragmented care. This risk is partially mitigated by an established practice of referral and coordination among specialists, facilitated by relationships of trust between addiction treatment services, psychiatric units, and other departments, which makes it relatively easy to draw on specific expertise in managing complex cases. Among the main critical factors identified are barriers to access linked to stigma and, in some contexts, prejudiced attitudes on the part of non-specialist providers, which hinder access to and continuity of care and exacerbate the vulnerability and marginalization of these women. Among the success factors, however, is the constant dialogue between clinical and psychosocial practitioners, which is particularly important when a woman begins a treatment course while maintaining a connection to her substance-use context—in clinical and social situations that require a high degree of coordination and flexibility.
In this context, Clinical Pharmacology and Toxicology can play a specific role: contributing to harm prevention and reduction (screening, brief interventions, referral to appropriate treatments); optimizing therapies for substance use disorders (SUD) and comorbidities by assessing the risk-benefit ratio during pregnancy; managing acute conditions in emergency and urgent care settings; and supporting the management of hospitalized patients already under the care of specialized addiction services. The goal is a collaborative effort among all services to benefit patients, with Pharmacology serving as a bridge to reduce harm, improve treatments, and strengthen prevention.
Motherhood is a pivotal stage in the lives of many women who use substances, and they should be supported with the same care and respect given to women who do not use substances.
Pharmacology and Clinical Toxicology
Institute of Pharmacological Sciences of Italian-speaking Switzerland
***Tradotto con DeepL***
Based on my clinical experience, I developed—as part of my final project for the CAS Addiction program—a structured protocol for the pharmacological and toxicological management of pregnant patients diagnosed with substance use disorder (SUD), which was developed based on an analysis of existing services in the region.
The use of legal (e.g., alcohol, nicotine) and/or illegal substances by women with DUS during pregnancy is a growing public health concern. Substance use during pregnancy increases the risk of adverse outcomes for both mother and child, including higher rates of morbidity and mortality, as well as potential consequences for neurodevelopment in later years. As an institute, we are often called upon to assess exposure to medications and substances during pregnancy. The presence of a substance use disorder makes intervention particularly complex, as it occurs within the context of poly-substance use and comorbidities—often psychiatric in nature—that require appropriate pharmacological treatments even during pregnancy. This takes place against a backdrop that is highly fragile from a biopsychosocial and relational standpoint, necessitating support for future parenthood and attention to legal and ethical implications.
Structured interviews were conducted with representatives of the services identified as being most involved: the Ingrado Addiction Service, the Cantonal Prison Health Service, the Cantonal Psychiatric Clinic of the Cantonal Sociopsychiatric Organization (OSC), and the OSC Psychosocial Services. In addition, the EOC departments that serve as the primary points of contact with women of childbearing age who use substances but are not being treated by specialized services (Emergency Department, Gynecology and Obstetrics, Infectious Diseases, Sexual Health Clinics, Neonatology) were identified, recognizing the crucial role of primary care physicians and pediatricians in the community.
According to all healthcare providers, in most cases patients arrive already pregnant, often with psychiatric comorbidities and on medication—sometimes complex; it is uncommon for them to request preconception optimization of their treatment to plan for pregnancy. The most commonly involved substances are cocaine, heroin, and cannabis, with an increase in cases related to stimulants (amphetamines, synthetic cathinones) and ketamine; among legal substances, alcohol, nicotine, and benzodiazepines are common. The family situation upon discovery of the pregnancy is often complex, and it is not uncommon for there to be no stable partner.
In summary, there appears to be a lack of shared protocols for the care of pregnant women with substance use disorders (SUD), posing a risk of fragmented care. This risk is partially mitigated by an established practice of referral and coordination among specialists, facilitated by relationships of trust between addiction treatment services, psychiatric units, and other departments, which makes it relatively easy to draw on specific expertise in managing complex cases. Among the main critical factors identified are barriers to access linked to stigma and, in some contexts, prejudiced attitudes on the part of non-specialist providers, which hinder access to and continuity of care and exacerbate the vulnerability and marginalization of these women. Among the success factors, however, is the constant dialogue between clinical and psychosocial practitioners, which is particularly important when a woman begins a treatment course while maintaining a connection to her substance-use context—in clinical and social situations that require a high degree of coordination and flexibility.
In this context, Clinical Pharmacology and Toxicology can play a specific role: contributing to harm prevention and reduction (screening, brief interventions, referral to appropriate treatments); optimizing therapies for substance use disorders (SUD) and comorbidities by assessing the risk-benefit ratio during pregnancy; managing acute conditions in emergency and urgent care settings; and supporting the management of hospitalized patients already under the care of specialized addiction services. The goal is a collaborative effort among all services to benefit patients, with Pharmacology serving as a bridge to reduce harm, improve treatments, and strengthen prevention.
Motherhood is a pivotal stage in the lives of many women who use substances, and they should be supported with the same care and respect given to women who do not use substances.
Dr. Francesca Bedussi, M.D.
Specialist in Pharmacology and Clinical Toxicology
Postgraduate Certificate in Maternal-Fetal Medicine (University of Turin)
CAS in Addiction (University of Applied Sciences of Italian-speaking Switzerland)
Medical Specialist
Institute of Pharmacological Sciences of Italian-speaking Switzerland
***Tradotto con DeepL***
Domanda 3
Lorem ipsum dolo r sit amet, consectetur adipiscing elit. Quisque sed lacus eget felis consectetur pellentesque. Duis venenatis at nunc ut lacinia. Quisque vel porttitor massa, nec porta lacus. Pellentesque non nisi fringilla, aliquet elit vel, dignissim mi. Morbi convallis ligula nec enim molestie rutrum sollicitudin ut lorem.